Imatinib Mesylate (STI571)

Modify Date: 2024-01-02 11:06:11

Imatinib Mesylate (STI571) Structure
Imatinib Mesylate (STI571) structure
 Common Name Imatinib Mesylate (STI571)
CAS Number 220127-57-1 Molecular Weight 589.708
Density 0.858 g/mL at 25 °C(lit.) Boiling Point 133-134 °C(lit.)
Molecular Formula C30H35N7O4S Melting Point 214-224°C
MSDS Chinese USA Flash Point 64°F
Symbol GHS07
GHS07		 Signal Word Warning

 Use of Imatinib Mesylate (STI571)


Imatinib Mesylate is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.

 Names

Name imatinib methanesulfonate
Synonym More Synonyms

 Imatinib Mesylate (STI571) Biological Activity

Description Imatinib Mesylate is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
Related Catalog
Target

IC50: ~100 nM (c-Kit, Bcr-Abl, and PDGFR)[1]

In Vitro Imatinib (STI571) Mesylate inhibits c-Kit autophosphorylation, activation of MAPK, and activation of Akt without altering total protein levels of c-kit, MAPK, or Akt. The concentration that produces 50% inhibition for these effects is approximately 100 nM[1]. Imatinib (STI571) mesylate is very effective (in vitro IC50 of 25 nM) against the chronic myeloid leukemia-causing kinase Bcr-Abl. Imatinib also efficiently inhibits Kit (in vitro IC50, 410 nM) and PDGFR (in vitro IC50, 380 nM)[2]. Imatinib (STI571) mesylate is a multi-target inhibitor of v-Abl, c-Kit and inhibits Bcr/Abl, v-Abl, Tel/Abl, the native PDGFβ receptor, and c-Kit, but it does not inhibit Src family kinases, c-Fms, Flt3, the EGFR or multiple other tyrosine kinases. Imatinib inhibits tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC50 of approximately 0.5 μM in each case, but it has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2[3]. Imatinib mesylate selectively inhibits the activity of Bcr/Abl, c-Kit and PDGFR kinases. Imatinib mesylate reveals distinct and rapid antileukemic activity in chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL)[4].
In Vivo Animals treated with Imatinib Mesylate show a decrease of mean body weight throughout the whole study. Body weight loss is noticeable in mice from groups that receive chemotherapy and the vitamin D analog combined treatment. The body weight decrease of mice treat with both combined Imatinib mesylate and PRI-2191 is the highest (15%) on Day 22 of the experiment, but after that day, mice start to recover[4]. In a rat Ischemia/reperfusion injury (IRI) model, Imatinib mesylate attenuates lung injury by an antipermeability and antiinflammatory effect. The delivery and function of Imatinib mesylate in the lung is also confirmed in this model[5].
Cell Assay Tested A549 cells are placed in 96-well flat-bottom plates at a density of 5×103 cells per well 24 h before the addition of the test compounds. The cells are incubated for 96 h with two different concentrations (10 and 100 nM) of PRI-2191 and concurrently with various concentrations of Imatinib mesylate (10, 100, 1000 and 10,000 ng/mL) and other cytostatic drugs (Docetaxel (DTX) or Idarubicin (ID) : 0.1, 1, 10, 100 ng/mL; Cisplatin (CIS): 1, 10, 100, 1000 ng/mL). The sulforhodamine B (SRB) assay is performed to evaluate the cytotoxic effect. As a result, IC50 is calculated for each separate experiment in Cheburator 0.4, Dmitry Nevozhay software[4].
Animal Admin Mice[4] NOD/SCID female mice, 12-16 weeks old, body weight of 20-25 g, are used. Mice are subcutaneously (s.c.) inoculated in the right flank of the abdomen with A549 tumor cells suspension (5×106 cells in 0.2 mL of Hank’s medium per mouse, Day 0) and then are randomized into groups receiving varied combinations of vitamin D analogs and chemotherapeutics. One out of two experimental protocols is applied in the respective experiments: 1. The treatment is started from Day 7 after inoculation of tumor cells (when tumors become palpable). Imatinib mesylate is administered intraperitoneally (i.p.) at a dose of 75 mg/kg/day, daily for 19 days (from Days 7-25). PRI-2191 is administered s.c. or by oral gavage at a dose of 2 μg/kg/day, 3 times a week (on Days 7, 12, 14, 16, 19, 21 and 23). 2. The treatment is started from Day 7 after inoculation of tumor cells (when tumors become palpable). Imatinib mesylate is administered intraperitoneally (i.p.) at a dose of 50 mg/kg/day, daily for 13 days (from Days 7-19). PRI-2191 and PRI-2205 are administered s.c. at doses of 1 or 10 μg/kg/day, respectively, 3 times a week (on Days 7, 10, 12, 14, 17, 19, 21, 24 and 26). At the end of the experiments, blood is collected under anesthesia; then, the mice are sacrificed. Rats[5] Male Lewis rats weighing 270 to 320 g are used in the experiments. Imatinib mesylate (50 mg/kg) is injected intraperitoneally in the Imatinib group (n=7), and 0.5 mL of 20% DMSO without Imatinib is administered in the vehicle group (n=7). The dose of 25 mg/kg is preliminarily tested, and it produces a little improvement in lung function without statistical significance. The dose of 50 mg/kg and intraperitoneal administration are adopted based on this result and past reports. The animals undergo left thoracotomy, and the left hilum is occluded with a small metallic clamp. The occlusion is performed 20 minutes after Imatinib or vehicle administration. During clamping, the tidal volume (TV) and respiratory rate (RR) are adjusted to 8 mL/kg and 80 breaths/min, respectively. After 90 minutes of ischemia, the clamp is removed and reperfusion is maintained for 120 minutes. During reperfusion, blood flow and ventilation are restored in the bilateral lung. In the sham group (n=6), the animals are heparinized, thoracotomized, and ventilated for 210 minutes.
References

[1]. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.

[2]. Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

[3]. Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8

[4]. Maj E, et al. Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model. Int J Mol Sci. 2015 Nov 13;16(11):27191-207.

[5]. Tanaka S, et al. Protective Effects of Imatinib on Ischemia/Reperfusion Injury in Rat Lung. Ann Thorac Surg. 2016 Jul 23. pii: S0003-4975(16)30523-9

[6]. Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.

 Chemical & Physical Properties

Density 0.858 g/mL at 25 °C(lit.)
Boiling Point 133-134 °C(lit.)
Melting Point 214-224°C
Molecular Formula C30H35N7O4S
Molecular Weight 589.708
Flash Point 64°F
Exact Mass 589.247131
PSA 149.03000
LogP 5.19690
Index of Refraction n20/D 1.401(lit.)
Storage condition -20°C Freezer

 Safety Information

Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302
Precautionary Statements P301 + P312 + P330
Hazard Codes Xn
Risk Phrases 22
Safety Phrases S16-S26-S36/37/39
RIDADR UN 1993 3/PG 2
WGK Germany 3
Packaging Group II
Hazard Class 3
HS Code 2933990090

 Customs

HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Articles3

More Articles
Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.

Prostate 75 , 923-35, (2015)

Imatinib mesylate is a chemotherapeutic drug that inhibits the tyrosine kinase activity of c-KIT and has been successfully used to treat leukemias and some solid tumors. However, its application for t...

Evaluation of the toxic effects of four anti-cancer drugs in plant bioassays and its potency for screening in the context of waste water reuse for irrigation.

Chemosphere 135 , 403-10, (2015)

Anti-cancer drugs are compounds that are of high environmental relevance because of their lack of specific mode of action. They can be extremely harmful to living organisms even at low concentrations....

Transcription factors Sox5 and Sox6 exert direct and indirect influences on oligodendroglial migration in spinal cord and forebrain.

Glia 64 , 122-38, (2016)

Transcription factors of the SoxD protein family have previously been shown to prevent precocious specification and terminal differentiation of oligodendrocyte progenitor cells in the developing spina...

 Synonyms

4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide methanesulfonate
MFCD04307699
Imatinib mesylate
Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)
Imatinib mesilate (JAN)
Methansulfonsäure--4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzolcarboxamid(1:1)
4-[(4-Methyl-1-piperazinyl)methyl]-N-(4-methyl-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}phenyl)benzamide methanesulfonate
Imantinib mesylate
4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide methanesulfonate (1:1)
Gleevac
GLEEVEC
Imatinib mesilate
4-[(4-Methyl-1-piperazinyl)methyl]-N-(4-methyl-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}phenyl)benzamide methanesulfonate (1:1)
Glivec
STI-571
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Imatinib Mesylate (STI571) suppliers

Price: $66/10mM*1mLinDMSO

Reference only. check more Imatinib Mesylate (STI571) price

Related Compounds: More...
IMATINIB MESYLATE
60623-74-7
Imatinib (STI571)
152459-95-5
N-Desmethyl imatinib mesylate
404844-03-7
Imatinib-d8 mesylate
1092942-83-0
Imatinib D8
1092942-82-9
Imatinib Para-diaminomethylbenzene Impurity-d3
1246819-27-1
IMatinib Para-diaMinoMethylbenzene
1026753-54-7
Imatinib Impurity E
1365802-18-1
Imatinib hydrochloride
862366-25-4
3-Hydrazinyl-6-(thiophen-3-yl)pyridazine
1249618-66-3
6-(Trifluoromethyl)benzo[D]oxazole-2-carboxylic acid
944898-58-2
4-(Piperidin-2-yl)pyrimidine
1248619-27-3
(cyclobutylmethyl)[(1H-indol-3-yl)methyl]amine
1248515-73-2
4-Bromo-1-((4-methoxybenzyl)oxy)-2-nitrobenzene
1308452-09-6
3-[(5-Bromo-3-nitro-2-pyridinyl)oxy]-N,N-dimethyl-1-propanamine
1288993-36-1
Methyl 2-amino-3-chloroisonicotinate
1823921-98-7
4-(Azidomethyl)-2-bromo-1-fluorobenzene
1249743-93-8
2-azido-N-(4-chloro-2-fluorophenyl)acetamide
1247430-64-3
N1-(3-bromopyridin-2-yl)ethane-1,2-diamine
1289271-23-3
Chemsrc provides Imatinib Mesylate (STI571)(CAS#:220127-57-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Imatinib Mesylate (STI571) are included as well.>> amp version: Imatinib Mesylate (STI571)

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved